In last trading session, Editas Medicine Inc (NASDAQ:EDIT) saw 2.07 million shares changing hands with its beta currently measuring 2.07. Company’s recent per share price level of $1.37 trading at -$0.14 or -9.27% at ring of the bell on the day assigns it a market valuation of $113.67M. That closing price of EDIT’s stock is at a discount of -546.72% from its 52-week high price of $8.86 and is indicating a premium of 18.25% from its 52-week low price of $1.12. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.41 million shares which gives us an average trading volume of 4.29 million if we extend that period to 3-months.
For Editas Medicine Inc (EDIT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.60. Splitting up the data highlights that, out of 9 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.59 in the current quarter.
Editas Medicine Inc (NASDAQ:EDIT) trade information
Upright in the red during last session for losing -9.27%, in the last five days EDIT remained trading in the red while hitting it’s week-highest on Friday, 03/07/25 when the stock touched $1.37 price level, adding 25.1% to its value on the day. Editas Medicine Inc’s shares saw a change of 7.87% in year-to-date performance and have moved -23.03% in past 5-day. Editas Medicine Inc (NASDAQ:EDIT) showed a performance of 16.10% in past 30-days. Number of shares sold short was 13.77 million shares which calculate 2.31 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 9 to the stock, which implies a rise of 84.78% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -264.96% in reaching the projected high whereas dropping to the targeted low would mean a loss of -264.96% for stock’s current value.
Editas Medicine Inc (EDIT) estimates and forecasts
This year revenue growth is estimated to fall -60.93% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 873.44k for the same. And 9 analysts are in estimates of company making revenue of 1.43M in the next quarter. Company posted 1.14M and 513k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -1.48% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 50.77% while estimates for its earnings growth in next 5 years are of 23.95%.
Editas Medicine Inc (NASDAQ:EDIT)’s Major holders
Insiders are in possession of 0.32% of company’s total shares while institution are holding 66.15 percent of that, with stock having share float percentage of 66.36%. Investors also watch the number of corporate investors in a company very closely, which is 66.15% institutions for Editas Medicine Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at EDIT for having 8.03 million shares of worth $37.51 million. And as of 2024-06-30, it was holding 9.8032 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 7.78 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.498 of outstanding shares, having a total worth of $36.34 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.59 shares of worth $3.55 million or 3.12% of the total outstanding shares. The later fund manager was in possession of 2.26 shares on Dec 31, 2024 , making its stake of worth around $3.09 million in the company or a holder of 2.72% of company’s stock.
